Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Recombinant human interleukin-21

EU orphan designation number: EU/3/04/226
Active ingredient: Recombinant human interleukin-21
Indication: Treatment of renal cell carcinoma
Sponsor: Bristol-Myers Squibb International Corporation
Parc de l’Alliance, Avenue de Finlande 8, B-1420 Braine-l’Alleud, Belgium

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/09/2004 Centralised Orphan - Designation EMEA/OD/035/04 (2004)3422 of 02/09/2004
13/10/2009 Centralised Orphan - Transfer of orphan designation EMEA/OD/035/04/T/01 (2009)7917 of 09/10/2009
28/09/2012 Other procedure EMEA/OD/035/04
26/10/2012 Centralised Orphan - Transfer of orphan designation EMEA/OD/035/04/T/02 (2012)7689 of 24/10/2012
02/06/2014 Centralised Orphan - Removal of orphan designation from Community Register